Company profile
CITIUS PHARMACEUTICALS, INC.
NASDAQ:CTXRBiotechnology: Pharmaceutical Preparations
Drug pipeline (1)
| Asset | Stage | Revenue | Trials | Status |
|---|---|---|---|---|
| SUPRENZA | approved | — | 0 | — |
Revenue is the latest quarter the company reported for that product, from SEC filings; a fourth quarter is the year less nine months when no filing states one. Trial counts are of the product's ingredients, deduplicated by trial, so products sharing an ingredient share trials.
Clinical trials (2)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT05348200 | phase2 | completed | 2022-04-22 | 2023-04-20 | Citius Pharmaceuticals, Inc. | Safety and Efficacy of CITI-002 in Adult Patients With Moderate Grade Hemorrhoids |
| NCT02689856 | phase2 | completed | 2015-05-01 | 2015-09-01 | Citius Pharmaceuticals, Inc. | Safety and Efficacy of Hydrocortisone and Lidocaine Treatment of Grade I and II Hemorrhoids |
FDA applications (1)
| Application | Approved | Type | Applicant | Products | ||||
|---|---|---|---|---|---|---|---|---|
| NDA 202088 | 2011-06-13 | NDA | CITIUS PHARMACEUTICALS LLC | |||||
Loading… | ||||||||